Sharpe-Strumia Research Foundation
About
The mission of the Sharpe-Strumia Research Foundation is to encourage and support the conduct of medical research by practicing physicians on the medical staff of Main Line Hospitals with preference given to physicians whose primary hospital affiliation is the Bryn Mawr Campus, and to research which relates to identified clinical initiatives at the Bryn Mawr campus and Main Line Hospitals.
Collaborative studies with outside individuals or institutions (with preference given to other Jefferson Health System campuses) are encouraged, provided that such studies include active involvement of the practicing physician-investigator and are likely to lead to clinical trials at the Bryn Mawr or other Main Line Hospital campuses.
Contact us:
130 South Bryn Mawr Avenue
C-Wing, 6th Floor, Room 650
Bryn Mawr, PA 19010
Phone: 484.337.4244 | Fax: 484.337.4245
Instructions for submitting your proposal application
Submit a completed PDF version of your proposal to: sharpestrumiafoundationoffice@mlhs.org and 8 hard-copies by noon on February 1, 2024 to:
Louise Gethers
Sharpe-Strumia Research Foundation Office
130 South Bryn Mawr Avenue
6th Floor / C-Wing, Room 650
Bryn Mawr, PA 19010
For further information
Contact Louise Gethers at 484.337.4244 or email GethersL@mlhs.org
Instructions for submission of proposals
Format
- Be sure to use the format indicated on our main page.
- Only proposals adhering to the 6-page limit will be considered.
- Please do not include more than 20 publications with an investigator’s Curriculum Vitae.
- Appendices are strictly limited to 1 full length publication or equivalent, and 5 publication face pages.
- Please include a sample of your informed consent form if your research involves human subjects.
Budget
- Please use the Budget Form (Excel) available on our opportunities webpage when you submit the budget for your proposal.
- Travel costs for presentation of funded research should not be included in the project budget. The foundation has a separate fund for such expenses. Please review the foundation’s travel policy on our website or contact Louise Gethers for further details.
Intellectual Property Policy
- You agree to the foundation’s Intellectual Property Policy.
Additional information is available from Louise Gethers, Room 650, 6th floor C- wing, Bryn Mawr Hospital, 484.337.4244.
Additional special instructions
- Grant application deadline is February 1, 2024
- PC users are advised to complete the grant application (the body of the grant proposal, not the forms) using Arial 11 point font; Mac users should use Helvetica 11 point font
- Other support — include Specific Aims of each funded grant, along with title, principal investigator(s), funding source, dollar amount of award, inclusive dates
- Intellectual property — report any patents obtained or applied for as well as current business collaborations that relate directly to this proposal
- Human subjects description on research plan — describe the use of human subjects; state whether IRB approval was obtained or is being applied for
- Letters of collaboration — a signed letter of collaboration (indicating review of the grant submitted and willingness to participate in the project) is required from any co-investigator or senior-level collaborator (this excludes co-investigators who are listed on a Biographical Sketch and have submitted a Conflict of Interest form; also excluded are laboratory technicians, study nurses, students, residents and fellows-in-training)
- Appendices — limited to ONE principal investigator or co-investigator complete published reference or accepted/submitted manuscript that relates directly to the proposed project; the FACE pages only of no more than five publications or face pages/abstracts of any unpublished manuscripts may be submitted as additional support
- Conflict of Interest Forms — must be included for all key personnel on the project
Bryn Mawr Hospital
SSRF2023-04 Michael Ezekowitz, M.D. “Develop a protocol for a pilot study involving a prospective randomized comparison of the four approved direct-acting oral anticoagulants in elderly patients with atrial fibrillation”
SSRF2023-10 Laurence Belkoff, M.D. “Role of rhPSMA-7.3 PET/CT imaging in men with High-Risk prostate cancer following conventional imaging and associated changes in medical management”
Continuing Research BMH
SSRF2022-16 Ext Ashlie Burkart, M.D. “Spatial Transcriptomics of Leaky Gut”
Lankenau Institute of Medical Research
SSRF2023-01 Laura Mandik-Navak Ph.D. “Unraveling the mechanism by which therapeutic targeting of ID02 alleviates autoimmune arthritis”
SSRF2023-02 James Mullin, Ph.D. “Intestinal Barrier Dysfunction in Rheumatoid Arthritis”
SSRF2023-03 Susan Gilmour, Ph.D. “Biomarkers for Neutrophil Extracellular Trap Formation in Ovarian Cancer Patients”
SSRF2023-05 Ali Keramati, M.D. “Acute Hemodynamic Effects of Left Bundle Branch Versus Deep Septal Area Pacing”
SSRF2023-06 Alexander Burashnikov “Burden of atrial fibrillation and extracellular potassium in experimental and clinical settings”
SSRF2023-07 Margaretha Wallon, Ph.D. “ROS-blockade for prevention and treatment of chemotherapy-induced nerve cell damage”
SSRF2023-12 Eric Alexander, Ph.D. “Polyamine, ATP13A3, and GCN2-related biomarkers in cancer patients treated with immunotherapy”
SSRF2023-13 Basel Ramlawi, M.D. “Development of Clinical and Anatomic Risk Prediction Tools for Trans-Catheter Valve Interventions”
SSRF2023-14 Lisa Laury-Kleintop, Ph.D. “Defining RhoB antibody effects on B cell-associated responses and signaling in Rheumatoid Arthritis Patients”
SSRF2023-15 Sunil Thomas, Ph.D. “Microbial metabolome as a predictor of response to ulcerative colitis immunotherapy”
SSRF2023-16 Gan Xin-Yan, M.D. “Validation of an Efficient Method for Determination of Drug Dissociation Time Constant from Heart Ina Channels”
SSRF2023-17 Anthony Ashton, Ph.D. “Understanding the Pathogenic Basis of Pregnancy Induced Heart Failure”
SSRF2023-18 Scott Dessain, M.D. “Therapeutic potential of targeting the NMDA receptor in lung cancer”
Continuing Research LIMR
SSRF2022-03 Ext Sunil Thomas, M.D. “Development of MNRNA BINI therapy for the treatment of ulcerative colitis”
SSRF2022-14 Ext James Mullin, Ph.D. "Decreasing Upper Gastrointestinal mucosal leak by orally administered zinc”
SSRF2021-06 Ext 2 Sunil Thomas, Ph.D. “Molecular mechanisms leading to ulcerative colitis”
SSRF2021-22 Ali Keramati, M.D. “Comparison of left bundle branch area versus right ventricular pacing in patients with high-degree conduction disease after transcatheter aortic valve replacement”
Board members
Jack L. Martin, MD
President 2016–Present
Vice President 2014–2016
President 1998–2008
Guy T. Bernstein, MD
Vice President
Barbara S. Lindsay, MSN, RN
Treasurer and Secretary
Lawrence L. Livornese, Jr., MD
Chairman of Medicine, Main Line Health
Ex-Officio
John T. Schwarz
President, Bryn Mawr Hospital
Ex-Officio
Gary H. Friday, MD
Hans H. Liu, MD
James M. Mullin, PhD
Louise Gethers, Office Secretary
Foundation Accountant